Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Clinical Pharmacology
Published in: BMC Clinical Pharmacology 1/2006

Open Access 01-12-2006 | Research article

Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay)

Authors: Tanmay S Panchabhai, Shaun F Noronha, Sanish Davis, Vishal M Shinde, Nilima A Kshirsagar, Nithya J Gogtay

Published in: BMC Clinical Pharmacology | Issue 1/2006

Login to get access

Abstract

Background

Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).

Methods

All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.

Results

It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).

Conclusion

A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.
Appendix
Available only for authorised users
Literature
1.
Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol. 1997, 37: 269-96. 10.1146/annurev.pharmtox.37.1.269.CrossRefPubMed
2.
McLeod HL, Evans WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001, 41: 101-21. 10.1146/annurev.pharmtox.41.1.101.CrossRefPubMed
3.
Weinshilboum R: Inheritance and drug response. N Engl J Med. 2003, 348: 529-537. 10.1056/NEJMra020021.CrossRefPubMed
4.
Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003, 348: 538-549. 10.1056/NEJMra020526.CrossRefPubMed
5.
Evans WE, Johnson JA: Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2001, 2: 9-39. 10.1146/annurev.genom.2.1.9.CrossRefPubMed
6.
7.
Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002, 41: 913-58. 10.2165/00003088-200241120-00002.CrossRefPubMed
8.
Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ: Differences in diazepam pharmacokinetics in Chinese and white Caucasians – relation to body lipid stores. Eur J Clin Pharmacol. 1987, 32: 211-5. 10.1007/BF00542199.CrossRefPubMed
9.
Daly AK: Pharmacogenetics of the cytochromes P450. Curr Top Med Chem. 2004, 4: 1733-44. 10.2174/1568026043387070.CrossRefPubMed
10.
Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 1998, 8: 129-135. 10.1097/00008571-199804000-00006.CrossRefPubMed
11.
Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997, 7: 59-64. 10.1097/00008571-199702000-00008.CrossRefPubMed
12.
Herrlin K, Massele AY, Rimoy G, Alm C, Rais M, Ericsson O, Bertilsson L, Gustafsson LL: Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clin Pharmacol Ther. 2000, 68: 189-98. 10.1067/mcp.2000.108583.CrossRefPubMed
13.
Chang M, Tybring G, Dahl M-L, Götharson E, Sagar M, Seensalu R, Bertilsson L: Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol. 1995, 39: 511-518.CrossRefPubMedPubMedCentral
14.
Somogyi AA, Reinhard HA, Bochner F: Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmacol. 1996, 41: 175-179.CrossRefPubMed
15.
Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998, 129: 1027-30.CrossRefPubMed
16.
Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Okumura K: CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther. 1999, 66: 528-534. 10.1016/S0009-9236(99)70017-2.CrossRefPubMed
17.
Lamba JK, Dhiman RK, Kohli KK: CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther. 2000, 68: 328-35. 10.1067/mcp.2000.109365.CrossRefPubMed
18.
Rosemary J, Adithan C, Padmaja N, Shashindran CH, Gerard N, Krishnamoorthy R: The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians. Eur J Clin Pharmacol. 2005, 61: 19-23. 10.1007/s00228-004-0833-1.CrossRefPubMed
19.
Ethical Guidelines for Biomedical Research in Human subjects of the Indian Council of Medical Research. 2000
20.
Kobayashi K, Chiba K, Sohn DR, Kato Y, Ishizaki T: Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. J Chromatogr. 1992, 579: 299-305.CrossRefPubMed
21.
Malhotra KC: Morphological composition of the people of India. J Hum Evol. 1978, 7: 45-63. 10.1016/S0047-2484(78)80035-9.CrossRef
22.
de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995, 58: 404-11. 10.1016/0009-9236(95)90053-5.CrossRefPubMed
23.
Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther. 1995, 57: 662-629. 10.1016/0009-9236(95)90229-5.CrossRefPubMed
24.
Sim SCM, Aklillu E, Edwards RJ, Ahlberg S, Bertilsson L, Ingelman-Sundberg M: Identification of an CYP2C19 allele (CYP2C19*1D) causing enhanced expression. Proceedings Of The International Symposium On Microsomes And Drug Oxidations; 2004 Jul 4–9; Mainz, Germany. Mainz: The Symposium. 2004
Metadata
Title
Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay)
Authors
Tanmay S Panchabhai
Shaun F Noronha
Sanish Davis
Vishal M Shinde
Nilima A Kshirsagar
Nithya J Gogtay
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Clinical Pharmacology / Issue 1/2006
Electronic ISSN: 1472-6904
DOI
https://doi.org/10.1186/1472-6904-6-8

Other articles of this Issue 1/2006

BMC Clinical Pharmacology 1/2006 Go to the issue

Research article

Finasteride induced depression: a prospective study

Case report

Serum sickness-like reaction associated with cefazolin

Technical advance

High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection

Research article

Single and multiple dose pharmacokinetics of maritime pine bark extract (Pycnogenol) after oral administration to healthy volunteers

Case report

Hemolytic uremic syndrome following the infusion of oxaliplatin: case report

Research article

Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy